Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma

Cancer ◽  
2009 ◽  
Vol 115 (9) ◽  
pp. 1995-2003 ◽  
Author(s):  
Lizhi Liu ◽  
Shaobo Liang ◽  
Li Li ◽  
Yanping Mao ◽  
Linglong Tang ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Nasopharyngeal Carcinoma ◽  
Cranial Nerve ◽  
Prognostic Impact ◽  
Resonance Imaging ◽  
Cranial Nerve Involvement ◽  
Nerve Involvement

The Value of Magnetic Resonance Imaging and Clinical Examination in the Diagnosis of Nasopharyngeal Carcinoma Infiltration Along Cranial Nerve

2020 ◽  
Vol 10 (8) ◽  
pp. 1863-1868
Author(s):  
Manyi Li ◽  
Fuwei Cheng ◽  
Jisheng Liu ◽  
Temucin Mustafa
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Nasopharyngeal Carcinoma ◽  
Clinical Diagnosis ◽  
Clinical Examination ◽  
Cranial Nerve ◽  
Resonance Imaging ◽  
Positive Rate ◽  
Mri Diagnosis ◽  
Magnetic Resonance Imaging Mri

Objective: To study the value of magnetic resonance imaging (MRI) in the diagnosis of nasopharyngeal carcinoma with pericranial infiltration. Methods: 86 patients with nasopharyngeal carcinoma were selected as the research objected and examined by MRI and clinical examination, and the results of the two methods were compared. Results: In MRI examination, the positive rate of cranial nerve infiltration in nasopharyngeal carcinoma was 23.26%, which was significantly higher than 8.13% in clinical diagnosis. The coincidence rate between clinical diagnosis and MRI diagnosis was 35.00%. Conclusion: Nuclear MRI has important application value in the diagnosis of cranial nerve infiltration of nasopharyngeal carcinoma, which is worthy of clinical promotion.

Cranial Nerve Involvement in Nasopharyngeal Carcinoma: Response to Radiotherapy and its Clinical Impact

2006 ◽  
Vol 115 (5) ◽  
pp. 340-345 ◽  
Author(s):  
Jian-Cheng Li ◽  
Nina A. Mayr ◽  
William T. C. Yuh ◽  
Jian Z. Wang ◽  
Guo-Liang Jiang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cranial Nerve ◽  
Clinical Impact ◽  
Cranial Nerve Involvement ◽  
Nerve Involvement

scholarly journals Early intra-treatment diffusion weighted magnetic resonance imaging in patients with recurrent nasopharyngeal carcinoma treated with nivolumab

2020 ◽  
Vol 6 (3) ◽  
pp. 568
Author(s):  
Tiffany Y. So ◽  
Qi-Yong Ai ◽  
Brigette B.Y. Ma ◽  
Ann D. King
Keyword(s):  
Magnetic Resonance Imaging ◽  
Overall Survival ◽  
Magnetic Resonance ◽  
Nasopharyngeal Carcinoma ◽  
Progression Free Survival ◽  
Tumour Volume ◽  
Resonance Imaging ◽  
Free Survival ◽  
Diffusion Weighted ◽  
Weighted Magnetic Resonance Imaging

<p class="abstract">Immune check point inhibitors have demonstrated promising efficacy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) in phase I and phase II trials. Early identification of treatment response is important in these patients. This report aimed to document the early intratreatment diffusion weighted magnetic resonance imaging (DW-MRI) findings in NPC patients following treatment with the programmed cell death-1 inhibitor, nivolumab. Two consecutive patients with histologically confirmed recurrent undifferentiated NPC treated with nivolumab were prospectively recruited. Nivolumab was administered at a dosage of 3 mg/kg intravenously every 2 weeks. Patients underwent magnetic resonance imaging examinations at baseline, and at 3 and 5 weeks after commencement of treatment. Intratreatment changes in tumour volume and apparent diffusion coefficient (ADC<sub>mean</sub>)were calculated. The endpoints were objective response by response evaluation criteria in solid tumors and survival. In patient 1, an intratreatment ADC increase at 5 weeks corresponded with anatomical tumour volume reduction and a better long-term survival outcome (progression free survival 1.3 years, overall survival 2.9 years). In patient 2, an intratreatment ADC decrease at 5 weeks corresponded to progressive disease and worse outcome (progression free survival 0.0 years, overall survival 0.9 years). Intratreatment ADC changes at 3 weeks were not associated with response outcome. These cases suggest that intratreatment changes in ADC at 5 weeks may potentially predict tumour response in patients treated with nivolumab. Dedicated studies are needed to clarify these findings and fully characterise patterns of treatment related ADC change.</p>

Sign in / Sign up

Export Citation Format

Share Document